What Is Ibogaine?

Ibogaine, in one paragraph

Ibogaine is a naturally occurring psychoactive indole alkaloid found in the root bark of Tabernanthe iboga, a shrub native to West Central Africa, where it has been used for centuries in the Bwiti spiritual tradition. Since the 1960s it has been investigated as a possible interrupter of opioid dependence, and more recently for the neuropsychiatric effects of traumatic brain injury. A single oral dose produces a long inward state lasting roughly 12 to 36 hours. It is not approved by the FDA for any indication, it is a Schedule I controlled substance in the United States, and it prolongs the cardiac QT interval, which is why supervised programmes screen every patient with an EKG before administering it.

• Source: root bark of Tabernanthe iboga (Gabon, Cameroon and the surrounding region)
• Chemical class: indole alkaloid, also written as 12-methoxyibogamine
• Metabolism: converted by liver enzyme CYP2D6 into noribogaine, a long-lasting active metabolite
• US legal status: Schedule I, no accepted medical use, not FDA approved
• Principal risk: QT-interval prolongation via hERG potassium channel blockade

A plant medicine before it was a research compound

Tabernanthe iboga is a perennial rainforest shrub that grows in Gabon, Cameroon and neighbouring parts of West Central Africa. Its root bark contains a family of related compounds called iboga alkaloids. Ibogaine is the most studied of them, but it is one of more than a dozen present in the raw bark.

In the Bwiti tradition the root bark has been taken ceremonially for generations, in initiation rites and healing practices. That history matters, and it is also why the compound reached Western attention. Ibogaine's anti-addictive properties were not discovered in a laboratory. They were reported in the 1960s by people who had taken iboga for other reasons and noticed that their opioid withdrawal did not arrive.

Clinical programmes rarely use raw bark. The alkaloid content of root bark varies with the plant, its age and where it grew, which makes safe weight-based dosing impossible. Instead the compound is given either as purified ibogaine hydrochloride, a single molecule at a known concentration, or as a standardised total alkaloid extract. Those two forms behave differently and are not interchangeable.

Several mechanisms at once, and a metabolite that outlasts the dose

Ibogaine has no single target. It interacts simultaneously with opioid receptors, serotonin transporters, NMDA receptors and sigma receptors, and it has been shown to increase expression of glial cell line-derived neurotrophic factor, a protein involved in the growth and survival of neurons. That multi-target profile is unusual, and it is a large part of why the compound is difficult to study and difficult to imitate with a conventional single-target drug.

Metabolism matters as much as the parent compound. The liver enzyme CYP2D6 converts ibogaine into noribogaine, which is itself active and clears far more slowly. Published pharmacokinetic work in patients with opioid use disorder puts ibogaine's half-life at roughly 7.5 hours while noribogaine persists for around 28 to 49 hours. That is why people describe effects continuing for days after the acute experience has ended.

CYP2D6 activity is genetically variable. The same milligram-per-kilogram dose produces materially different blood levels in a poor metaboliser than in an extensive one, and clearance in published data rises steeply with CYP2D6 activity score. This is not a theoretical concern. It is a direct safety input, and it is the reason careful programmes consider metaboliser status alongside cardiac screening rather than dosing by body weight alone.

Where the research is actually pointed

What ibogaine is not

It is not a cure, and no honest programme will tell you otherwise. The published human evidence is dominated by observational studies and case series. The Stanford magnesium-ibogaine work in veterans is genuinely encouraging, and it involved 30 people with no control group. That is a signal worth taking seriously. It is not proof, and treating it as proof would be doing you a disservice.

It is not a recreational drug. This is the honest answer to a question people search for often. Ibogaine has no meaningful street trade and no real street names, because the experience is long, physically taxing and not euphoric. The words you will encounter refer to the plant or the preparation: iboga or eboka for the shrub, Bwiti for the tradition, ibogaine HCl for the purified salt, TA for total alkaloid extract.

It is not safe to take unsupervised. That is the part we would ask you to sit with. The documented deaths did not happen because ibogaine is uniquely poisonous. They happened in settings where nobody had checked a heart, reviewed a medication list, or corrected an electrolyte first.

Why cardiac screening is not a formality

Schedule I in the US, unscheduled in Mexico

Ibogaine is a Schedule I controlled substance under the United States Controlled Substances Act. That classification means no accepted medical use and no legal prescription or administration outside an authorised research setting. As of 2026 that has not changed.

Two things did change recently, and they are often reported as more than they are. In December 2025 the state of Texas awarded 50 million dollars to UTHealth Houston, in collaboration with UTMB Health, to lead multicentre ibogaine clinical trials in addiction, traumatic brain injury and other behavioural health conditions. And in April 2026 an executive order directed the FDA to prioritise review of psychedelic medicines, instructed the FDA and DEA to build a Right to Try pathway for eligible patients, and allocated federal research funding. Neither of those rescheduled ibogaine. They create the conditions under which rescheduling could eventually follow FDA approval.

Outside the United States the picture varies widely. Mexico does not schedule ibogaine, which is why supervised clinical programmes can operate there lawfully. That legal difference, not a loophole, is why patients travel. Our own programme runs in Cozumel under Mexican health regulation with physician oversight.

Validated instruments build your baseline before you travel.

Cardiac and vital monitoring around your session, read in real time.

Your progress re-scored against your baseline, in your portal.

Common questions

100% Confidential · No Obligation